Current Topics in Medicinal Chemistry - Online First
Description text for Online First listing goes here...
101 - 119 of 119 results
-
-
Benzoxathiolone-Thiazolidinone Hybrids: A New Class in the Search for Anticancer Agents
Authors: Eliza de Lucas Chazin, Ligia Souza da Silveira Pinto, Victor Facchinetti, Paula de Aquino Soeiro Portilho, Breno de Souza Bernardes, Claudia Regina Brandão Gomes, Emerson Lucena da Silva, Luína Benevides Lima, Felipe Pantoja Mesquita, Pedro Filho Noronha de Souza, Raquel Carvalho Montenegro, Marcus Vinícius Nora de Souza and Thatyana Rocha Alves VasconcelosAvailable online: 16 June 2025More LessBackgroundCancer continues to be a significant public health issue and one of the leading causes of death globally. In this context, developing new, potent, and more specific treatments against this disease is urgent.
MethodsA total of 15 benzoxathiolone-thiazolidinones hybrids were synthesized in a 5-step route and tested for their cytotoxicity against five human cancer cell lines: AGP-01 (gastric), SKMEL-103 (melanoma), HCT-116 (colon), CAL27 (tongue), and K562 (leukemia), as well as a non-tumoral cell line MRC-5.
ResultsCompounds 3-(6-hydroxy-2-oxobenzo[d][1,3]oxathiol-5-yl)-2-(4-nitrophenyl)thiazolidin-4-one and 2-(2,4-dichlorophenyl)-3-(6-hydroxy-2-oxobenzo[d][1,3]oxathiol-5-yl)thiazolidin-4-one exhibited good activity against the K562 leukemia cell line, with IC50 values of 4.0 μM and 5.3 μM, respectively. Docking studies demonstrated that these compounds likely bind to the BCR-ABL1 kinase, a key protein in the pathogenesis of chronic myeloid leukemia (CML).
ConclusionThe study suggests these benzoxathiolone-thiazolidinone hybrids could be promising lead compounds for developing new anticancer agents targeting leukemia.
-
-
-
Antibody-aptamer Complementation: Advancing Biosensing for Disease Monitoring
Authors: Thangavel Lakshmipriya and Subash C.B. GopinathAvailable online: 16 June 2025More LessA biosensor is a biological device designed to convert biological responses into an electrical signal, which has diverse applications across various fields, including diagnostics, environmental monitoring, food safety, and drug discovery. Among these, biosensing technology has achieved remarkable success in medical diagnostics. To detect target molecules for various probe molecules, such as nucleic acids, peptides, antibodies, and proteins are widely used. Of these, antibodies are well-established as remarkable molecules for detecting and monitoring a broad range of analytes. Recently, a novel class of molecules known as aptamers, often referred to as “artificial antibodies,” has gained significant attention from researchers for numerous biomedical applications, particularly in biosensing. Aptamers are synthetic molecules generated through a method called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Since aptamer and antibody have different bindings for target molecules, various biosensing techniques are utilized by using the combination of aptamer and antibody to enhance the biosensor. This combination possesses a unique and beneficial feature and holds the potential to drive significant advancements in sensing technology. Applying these combinations in biosensing technologies has some limitations due to the aptamer generation for some particular targets. This review explores recent applications of antibodies, aptamers, and their combined use in enhancing biosensing technologies and their limitations.
-
-
-
The Green Synthesis of Cu Nanoparticles and Investigation of the Antibacterial Properties and Cytotoxicity on Multidrug-Resistant E. coli
Authors: XiaoFeng Yuan and Yu WangAvailable online: 13 June 2025More LessIntroductionAlthough E. coli is considered a normal human microbiota, it may cause life-threatening infections such as septicemia, urinary tract infections, and enteric infections. Moreover, multidrug-resistant strains are a serious challenge in the clinic due to high mortality rates and the limited number of therapeutic options. Hence, the current study aimed to benefit from pink rose petals as a source of green synthesis of copper nanoparticles (Cu-NPs), to investigate the antibacterial features against multidrug-resistant E. coli, and to measure the cytotoxicity of Cu-NPs.
MethodsPink rose petals were used as a reducing agent for Cu-NP synthesis, and then XRD, zeta potential, UV-Vis, FTIR, SEM, and DLS analyses were performed to characterize the synthesized NPs. Moreover, the MIC and zone of inhibition values of Cu-NPs were measured and compared to common antibiotics. Additionally, the MTT assay was performed to assess the cytotoxicity.
ResultsThe green synthesized Cu-NPs were spherical and uniform with a size of ~200 nm. The MIC of Cu-NPs was 1024 μg/ml on the MDR strain of E. coli, representing the antibacterial activity comparable to levofloxacin (p-value>0.05) but less than imipenem and trimethoprim (p-value<0.001). Moreover, the CC50 of synthesized Cu-NPs was 731.2 μg/ml and significantly lower than the studied antibiotics (p-value<0.001).
ConclusionThe findings may suggest Cu-NPs as a promising antibacterial strategy against MDR strains of E. coli, however, further studies are encouraged to clarify the safety of optimized doses.
-
-
-
A Review of Research from 2012 to 2024 on Pyrazole-based Anticancer Agents with SAR Study
Authors: Deepali Wanode, Deweshri Nandurkar, Megha Ambatkar, Nilesh Rarokar and Pramod KhedekarAvailable online: 10 June 2025More LessThe field of cancer research has witnessed a surge in the exploration of novel therapeutic agents, with pyrazole derivatives emerging as promising candidates in the quest for effective anticancer treatments. This comprehensive review provides an in-depth analysis of the research landscape surrounding pyrazole derivatives as potential anticancer agents over the period from 2012 to 2024. Many synthetic pyrazole derivatives have been approved by the FDA and used as chemotherapeutic medicines, and some are under clinical trials, also reported in this article. The review aims to serve as a valuable resource for researchers, guiding future investigations and fostering the development of innovative pyrazole-based anticancer therapeutics.
-
-
-
Neurological Inflammation in Parkinsonism: Current Prognosticative Diagnostics and Pitfalls
Available online: 04 June 2025More LessParkinson's disease (PD) is a persistent neurological degenerative condition that can significantly alter one's quality of life. This condition affects the substantia nigra, the region of the brain that contains dopamine-producing neurons. It is a disorder of the central nervous system that arises when nerve cells, or neurons, in this brain area are damaged or die. Norepinephrine, another chemical messenger that aids in controlling primary physiological processes, such as heart rate and blood pressure, is also deficient in PD patients. The symptoms of PD can interfere with daily activities and include fatigue, walking difficulties, limb rigidity, and loss of smell. Researchers are striving to identify a reliable biomarker for Parkinson's disease. Currently, the Food and Drug Administration has approved the radiotracer I-123-ioflupane injection followed by scanning (DATscan-SPECT) for precise analysis. To diagnose Parkinson's disease early, researchers are developing predictive diagnostic techniques using various biomarkers. The right biosensor can recommend the best personalized course of action to slow the progression of Parkinson's disease. This review highlights the strong performance of diagnostic biomarkers for Parkinson's disease and emphasizes the effectiveness of the common immuno-, apta- and DNA-sensors for their efficient implementations for different biomarkers. Further, it also discusses the potential advantages and drawbacks associated with detection methods for improving high-performance diagnostics.
-
-
-
Unraveling Neurodegenerative Disorders: The Potential of Indole and Imidazole-Based Heterocycles
Available online: 02 June 2025More LessNeurodegenerative diseases present a considerable challenge to healthcare systems worldwide, prompting the exploration of innovative treatment strategies. Heterocyclic compounds, specifically those originating from the indole and imidazole structures, have garnered increasing interest due to their potential to protect neurons. Based on an in-depth literature survey, this review explores the Structure-Activity Relationship (SAR) and pharmacokinetics to reveal the active pharmacophores of various indole and imidazole analogs. We delve into the underlying molecular and cellular mechanisms involved in neurodegeneration, highlighting how indole and imidazole derivatives exert neuroprotective effects by modulating oxidative stress, inflammation, protein misfolding, inhibiting cholinesterase, and neuroinflammation. Finally, we address the challenges and prospects in translating these findings into clinical therapies, underscoring the need for continued research to optimize the safety and efficacy of heterocyclic compounds in the treatment of neurodegenerative disorders.
-
-
-
Prescription FINO2 and Pirfenidone Supported in Reducing Fibrosis in Mouse Breast Tumor Tissue by Targeting SLC7A11 and HMOX1
Available online: 29 May 2025More LessBackgroundBreast cancer has become the most commonly diagnosed cancer worldwide and represents a major burden to public health. Advances in understanding ferroptosis pathways and identifying new therapeutic targets raise hope for using ferroptosis modulators to treat untreatable diseases.
MethodsIn this study, BALB/c mice were divided into several groups: model, Doxorubicin-treated, FINO2-treated, Pirfenidone-treated, and a combined Pirfenidone + FINO2 group. After treatment, we assessed iron content in cancer cells, fibrosis area, CD34 expression, and mRNA levels of solute carrier family 7 member 11(SLC7A11) and heme oxygenase 1 (HMOX1).
ResultsResults showed that the average tumor size in the Pirfenidone + FINO2 group was significantly smaller than in the doxorubicin group. Treatments with FINO2, Pirfenidone, or their combination significantly increased iron content in cancer cells and reduced the fibrosis area. Co-treatment with FINO2 and Pirfenidone also led to notable decreases in CD34 expression and mRNA levels of SLC7A11 and HMOX1.
ConclusionThese findings suggest that FINO2 ferroptosis agonists, when combined with other anticancer agents like Pirfenidone, can enhance ferroptosis and reduce tumor fibrosis. Additionally, the overexpression of SLC7A11 and HMOX1 in breast cancer model mice is associated with increased tumor growth and reduced metastasis, indicating that targeting these proteins with specific inhibitors may be a promising strategy for breast cancer treatment.
-
-
-
Advances in the Directed Evolution of Computer-aided Enzymes
Authors: Zhiming Hu, Yijie Liu, Yonghong Huang and Peng YuAvailable online: 29 May 2025More LessExperimental-driven directed evolution has achieved remarkable success in enzyme engineering. However, it relies on random mutagenesis and high-throughput screening, both of which have certain limitations, particularly the randomness of mutagenesis and the extensive screening workload that slows down the method's rapid development. In contrast, computer-aided directed evolution combines computational simulations with experimental techniques, providing an efficient and precise approach to enzyme rational design and optimization. By integrating computational tools, researchers can streamline the enzyme design process, improving the accuracy of mutations and screenings, which in turn accelerates enzyme optimization. This review comprehensively introduces the commonly used methods and applications of computer-aided directed evolution, discussing the tools and techniques frequently used in protein sequence analysis and structural analysis. It also covers computational simulation and prediction strategies such as homology modeling, molecular docking, molecular dynamics simulations, machine learning algorithms, and virtual screening. These tools play a critical role in predicting the effects of mutations on enzyme function and optimizing enzyme performance. Moreover, the review explores widely adopted semi-rational and rational design strategies in enzyme engineering, which combine computational predictions with experimental validation to effectively improve enzyme performance. Additionally, the article delves into the challenges and bottlenecks encountered in applying computational technologies in directed evolution, including issues related to computational precision, data quality, and the complexity of enzyme-substrate interactions. Despite these challenges, the future of computer-aided directed evolution holds great promise, with advancements in computational power, machine learning, and multi-omics data integration offering tremendous potential to overcome current limitations.
In conclusion, this review aims to provide valuable insights for researchers in enzyme engineering, assisting them in developing new, efficient enzymes by integrating both experimental and computational approaches.
-
-
-
Design, Synthesis, Molecular Docking, and Biological Evaluation of 7-Phenyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones as Antibacterial Agents
Available online: 26 May 2025More LessBackgroundNew antibacterial agents are urgently needed as bacterial diseases, especially urinary tract infections (UTIs), are becoming more common, and antibiotic resistance is increasing.
AimsThis study aimed to design, synthesize, and conduct molecular docking and biological evaluation of pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones as antibacterial agents.
Methods7-Phenyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones were designed using an in silico approach. The designed compounds were synthesized using reported procedures. Molecular docking studies were carried out using the Maestro 12.9 module of Schrodinger software. QikProp module of the Schrodinger suite was used for in silico ADME evaluation of synthesized compounds. In vitro antibacterial activity of these compounds was assessed using the serial dilution method.
ResultsCompounds MA-03 and MA-12 showed potent antibacterial activity with MIC values of 1.56, 3.125, 1.56, and 6.25 µg/ml and 1.56, 3.12, 6.25, and 3.12 µg/ml, respectively, against Bacillus subtilis, Staphylococcus aureus, Pseudomonas putida, and Escherichia coli using controls ciprofloxacin and amoxicillin (0.78, 0.39, 1.56 and 0.39 µg/ml and 0.78, 3.125, 3.125, and 1.56 µg/ml). All the synthesized compounds demonstrated higher binding affinities against bacterial proteins with reference to amoxicillin and ciprofloxacin.
ConclusionAll the compounds exhibited antibacterial activity against all the tested strains of bacteria with optimum ADME profile.
-
-
-
Highlighting the Therapeutic Potential of an Underexplored Target: Human Dihydroorotate Dehydrogenase in Cancer, Rheumatoid Arthritis and Sclerosis
Authors: Shubham Dash, Rupali Verma, Shorya Thakur, Gurvinder Singh and Charanjit KaurAvailable online: 23 May 2025More LessIntroductionThe dihydroorotate dehydrogenase (DHODH) enzyme plays a crucial role in the de novo pyrimidine biosynthesis pathway, catalysing the conversion of dihydroorotate to orotate in the cells. This pathway is important for the synthesis of nucleic acids and vital molecules essential for homeostasis, cellular functioning, and survival. So, targeting this enzyme can be an effective approach for the treatment of cancer, arthritis, malaria, viral or microbial infections, and other autoimmune diseases.
MethodsIn this review, we have highlighted the therapeutic implications of DHODH inhibition in cancer, rheumatoid arthritis and multiple sclerosis through an extensive literature survey from various scientific databases like PubMed, Google Scholar, Science Direct, Embase, clinical trials.gov.in, Google Patents, etc.
ResultsWe have tried to identify the pharmacophores from synthetic, phytochemical, and microbial origins, effective as DHODH inhibitors. The effect of structural changes on activity has been summarised, providing insights into the efficacy and mechanisms of these inhibitors at the molecular level. Furthermore, this review also presents a comprehensive analysis of clinical trials and patents related to DHODH inhibition to extract the valuable information to be used for clinical drug development in cancer, rheumatoid arthritis, and multiple sclerosis.
ConclusionBy integrating data from synthetic, plant, and microbial sources, along with clinical trial and patent outcomes, this review highlights the diverse role of DHODH. Its inhibition offers a more targeted approach to reduce the proliferation of rapidly dividing cells while sparing normal cells, modulating specific immune responses. But, limiting understanding of resistance mechanisms and potential for toxicity are the current challenges. It offers a roadmap for future research and drug discovery endeavours focused on harnessing the beneficial potential of DHODH inhibition, including the development of novel inhibitors with improved selectivity and pharmacokinetics across a wide array of pathological conditions.
-
-
-
Pharmacological Potential of Jasminum auriculatum Extracts Ointment as an Anti Psoriatic Agent: In vivo Evaluation Using Swiss Albino Mice Model
Authors: Simran Aneja, Neerupma Dhiman, Arun Mittal, Bhupesh Sharma, Rishabha Malviya and Shivam RajputAvailable online: 21 May 2025More LessBackgroundSynthetic drugs are the drug of choice for topical treatment of psoriasis. However, these are associated with side effects; hence, there is a need to explore effective alternative treatments for psoriasis. Jasminum auriculatum has been used in Ayurvedic and traditional medicine as an ingredient for managing numerous skin ailments like eczema and ringworm.
PurposeThis study aimed to evaluate the in vivo study of ointments prepared from chloroform and methanolic extracts of Jasminum auriculatum for the treatment of psoriasis.
MethodsInitially, pharmacogenetic and physicochemical characterization of Jasminum auriculatum was performed to check their presence. The ointments prepared from chloroform and methanolic extracts of Jasminum auriculatum were screened for acute toxicity studies and antipsoriatic activity by IMQ-induced psoriasis in the Swiss albino mice ear model. The parameters like ear thickness, ear weight, erythema, scales, and infiltration (Permeation into the skin) were evaluated. The histopathological studies were also conducted to support the findings.
ResultsThe plant showed the presence of pharmacogenetic structures like Trichomes, Palisade cells, Xylem, Collenchyma Tous cells, Parenchymatous cells, Fibers, Pericyclic cells, Stomata, Phloem, and Sclerenchyma Tous cells responsible for the presence of phytoconstituents having antipsoriatic activity. The signs and symptoms increased in imiquimod-induced animals, but ointment of chloroform and methanolic extract of Jasminum auriculatum reduced the skin thickness, redness, scaling, and erythema. The study reveals along with the progression of disease topical formulation of the extract showed the effect on animals in a dose-dependent manner. Histopathological examination also supported the earlier results.
ConclusionsThe present study demonstrates that ointments of chloroform and methanolic extract of Jasminum auriculatum are safe and effective in the treatment of psoriasis, as revealed by the in vivo study. These preclinical results could further be explored for the development of other topical formulations used in humans.
-
-
-
Structure-Guided Development of Mycobacterial Thymidine Monophosphate Kinase (MtbTMPK) Inhibitors: Unlocking New Frontiers in Tuberculosis Research
Available online: 21 May 2025More LessResearchers are actively engaged in developing new antitubercular drugs targeting the enzyme Mycobacterial Thymidine Monophosphate Kinase (MtbTMPK). This newer target has specificity and selectivity over other thymidylate kinases and especially differs from human thymidylate kinase (hTMPK). Over the last two decades, various potent MtbTMPK inhibitors comprised of both nucleoside and non-nucleoside structures have been developed. Mostly, nucleoside inhibitors have encountered substantial challenges, primarily related to poor solubility and permeability, which often render them inactive in whole-cell antitubercular assays. Consequently, the focus has shifted towards identifying potent non-nucleoside inhibitors that demonstrate activity in whole-cell assays. Researchers have employed structure-based modifications and leveraged insights from co-crystal structures of Mycobacterium tuberculosis TMPK (MtbTMPK) with its natural substrate, thymidine monophosphate (TMP), to develop potent non-nucleoside inhibitors—such as cynopyridone and 5-methylpyridine analogues—which have demonstrated nanomolar enzyme inhibitory activity. However, the problem was persistent and only a few non-nucleoside inhibitors have been found to be active in whole-cell activity, likewise nucleoside inhibitors. The reason behind the uncertainty between enzyme inhibitory and whole cell antitubercular activity of developed inhibitors remains incomprehensible to date, even though the efflux pump and permeability-related studies have been performed. Despite numerous efforts, no antitubercular drug targeting MtbTMPK has reached the market or clinical trials, though some non-nucleoside inhibitors are in preclinical stages. As MtbTMPK is crucial for Mycobacterium tuberculosis survival and its inhibition effectively reduces the growth of the bacteria, making it a promising target for novel antitubercular drugs. In addition to thymidine-like core structures, several inhibitors with non-thymidine-like cores have also been developed as potent MtbTMPK inhibitors, opening new opportunities for future research to explore the uncharted chemical space of this target.
-
-
-
Traditional Chinese Medicines for Alzheimer's Disease: Current Knowledge, Clinical Applications, and Future Directions
Authors: Yu Deng, Chaojun Chen, Hongtao Li, Tianle Wang, Xu Zhang, Xueyang Wang and Guangtao PanAvailable online: 12 May 2025More LessAlzheimer's disease (AD) is a prevalent neurodegenerative disorder that poses a significant challenge to the health of the global aging population. Despite extensive research, the complex mechanisms underlying AD pathogenesis remain largely elusive. In recent years, a growing number of clinical studies have demonstrated the preventive and therapeutic potential of Traditional Chinese Medicine (TCM) against AD through multiple pathways, targets, and compounds. In this study, we conducted a review of the literature published over the past 20 years through international and domestic databases, including PubMed, Medline, Cochrane Library, CNKI, SinoMed, Wanfang, and VIP Journal Integration Platform. This review systematically evaluates current research advancements regarding single-herb preparations, bioactive constituents, and compound formulations in Traditional Chinese Medicine (TCM), with focused analysis on three therapeutic categories: tonifying herbs, blood-activating and stasis-eliminating agents, as well as orifice-opening, phlegm-resolving, and mind-stabilizing medicinal substances. Furthermore, this review discusses the potential mechanisms underpinning the anti-AD effects of TCMs. By integrating these insights, this review aims to establish a theoretical foundation for the application of TCMs in AD treatment and provide a reference for future pharmacological studies and the development of health-related products.
-
-
-
Targeting Cell Signalling Pathways with New Small Molecules in Inflammation and Cancer
Authors: Ritam Mondal, Kalpana Rahate and Sandhya ChaudharyAvailable online: 12 May 2025More LessIn the treatment of cancer and inflammation, small molecules become powerful therapeutic tools that provide new therapeutic approaches with improved efficacy and fewer side effects. This review offers a thorough summary of current developments in small-molecule drugs that target cancer and inflammatory pathways. Specifically, inhibition of phosphodiesterase-4 (PDE4) and COX receptors have demonstrated potential in the field of inflammation to help mitigate a variety of inflammatory disorders. We examine the structural design, mechanism of action, and therapeutic potential of innovative small compounds that inhibit or alter these pathways. Significant attention is placed on the dual anti-inflammatory and anti-cancer properties of these substances. The evaluation emphasizes preclinical and clinical data, revealing the most promising candidates under development. In summary, the precise manipulation of cellular signalling pathways by small compounds constitutes a dynamic domain with the capacity to revolutionize therapeutic approaches for inflammation and cancer. Ongoing investigation of these chemicals is essential for the advancement of safer and more efficacious therapies.
-
-
-
Integrative Analysis Reveals Genes Causal Relation with Ovarian Cancer and aging
Authors: Lan-hui Qin, Chongze Yang, Rui Song, Pei-yin Chen, Zijian Jiang, Weihui Xu, Guanzhen Zeng, Jin-yuan Liao and Liling LongAvailable online: 09 May 2025More LessBackgroundExploring the correlation between ovarian cancer and aging has great significance for understanding the pathogenesis of ovarian cancer and formulating targeted therapeutic regimens.
ObjectiveThis computational study aims to identify and validate key genes in monocyte subtypes related to ovarian cancer and aging, exploring potential causal relationships.
MethodsWe collected single-cell RNA sequencing data (GSE157007, GSE184880), GWAS data (14,049 samples and 40,941 controls from a European population), and eQTL data of ovarian cancer and aging. Using R software packages like Seurat and singleR, we conducted data integration, quality control, cell classification, and differential gene expression analysis to identify intersecting monocyte subtype genes in ovarian cancer and aging. We employed summary data-based Mendelian randomization (SMR) analysis and Heterogeneity in Dependent Instruments (HEIDI) tests to pinpoint causal genes. Further single-cell functional analyses (gene switching, cell communication, metabolic pathway analysis), Bulk RNA sequencing validation, functional enrichment, and protein-protein interaction (PPI) analyses elucidated these genes' biological roles.
ResultsThe dataset included 123,280 cells, revealing differential gene expression in classical monocytes (104 genes), intermediate monocytes (43 genes), and myeloid dendritic cells (39 genes). SMR and HEIDI identified causal relationships for 7 genes in classical monocytes, 3 in intermediate monocytes, and 3 in myeloid dendritic cells with ovarian cancer. Bulk RNA seq validation confirmed six monocyte genes as causal in ovarian cancer and aging. TREM1, SERPINB2, and CD44 were upregulated, while DST was downregulated; SLC11A1 and PNRC1 showed contradictory patterns. Interactions with NK and T cells involved LGALS9 - CD44/45 receptors. Riboflavin metabolism was a common enriched pathway.
ConclusionThis study identified six specific monocyte genes as potential therapeutic targets for ovarian cancer and aging.
-
-
-
Transforming Breast Cancer Therapy: The Pivotal Role of Nanoparticles
Authors: Lalit Kumar, Ritesh Rana, Isha Singh, Neelam Sharma, Vikas Aggarwal, Nisha Gupta and Vuluchala JyothiradityaAvailable online: 06 May 2025More LessIntroductionGlobally, breast cancer (BC) affects a greater number of women than any other kind of cancer, and it is the second leading cause of death after lung cancer. The current standard of care for cancer treatment is the surgical excision of the malignant tumor followed by adjuvant therapy with chemotherapy or radiation. Regrettably, the side effects of radiation and chemotherapy frequently cause harm to healthy tissues and organs, hence limiting the effectiveness of these treatments in addressing BC. Recently, various nanoparticles (NPs) have been discovered and manufactured with the capacity to selectively target cancerous cells while minimizing harm to normal cells or organs. As a result, the utilization of NPs-mediated targeted drug delivery systems (DDS) has emerged as a promising method for treating BC.
ObjectiveThe primary aim of this review was to provide a concise overview of the function of different nanoparticles in the specific delivery of anticancer medications to eradicate breast cancer.
MethodsThe present review paper performed a literature inspection using several search engines such as PubMed, Google Scholar, and Science Direct.
ResultsIn addition to their ability to selectively target tumor cells and minimize side effects, nanoparticles (NPs) possess other distinctive characteristics that make them highly desirable for cancer treatment. These include low toxicity, excellent compatibility, ease of preparation, high photoluminescence for in vivo bioimaging, and the capacity to efficiently load drugs due to their adjustable surface functionalities.
ConclusionThis study provides a comprehensive examination of recent therapeutic studies that utilize various nanoparticle-mediated drug delivery systems as alternatives to established therapy techniques for breast cancer. This study will elucidate the importance of nanoparticle-mediated drug delivery systems (DDS) and provide a roadmap for identifying the optimal approach for future targeted drug delivery, specifically for the treatment of breast cancer.
-
-
-
Optimization, Preparation, and Cytotoxic Potential of Pyrus communis Extract Loaded Ethosomes on Skin Cancer Cell Lines
Authors: Kiran Kangra, Vandana Garg, Anju Dhiman and Rohit DuttAvailable online: 02 May 2025More LessBackgroundSkin cancer is one of the most prevalent cancers globally and is considered a serious public health problem associated with high death rates. The current therapeutic regimes for skin cancer are limited by their low bioavailability, generation of resistance, or adverse side effects. Many fruit extract-based nutraceuticals hold potential as topical treatment methods. Pyrus communis (Pear) fruit extract is a rich source of cholinergic acid, presently used as therapy for various skin diseases. Thus, it qualifies as a promising candidate for skin cancer treatment.
ObjectiveThe objective of the study is to evaluate the cytotoxicity of Pyrus communis extract entrapped in ethosomes.
MethodsIn this study, Pyrus communis fruit extract was formulated in ethosomes using the hot method and optimized using central composite design. The optimized ethosomes were characterized in vitro for particle size distribution, zeta potential, entrapment efficiency, morphology, and particle stability.
ResultsPreliminary phytochemical screening results suggest that PCHE contains a significant amount of phenolic compounds compared to other extracts (PCEA and PCAE). The presence of these phenolic compounds contributes to the strong antioxidant and cytotoxic effects of PCHE, which are observed in a dose-dependent manner. Analysis through GC-MS has identified chlorogenic acid, arbutin, ursolic acid, quercetin, and epicatechin are present in PCHE. Based on the initial testing of the extracts, PCHE was chosen for the preparation of ethosomes. The optimized ethosomes were found to have a particle size of 699 nm and a zeta potential of -16.07. Transmission Electron Microscopy illustrated a closed, spherically symmetrical structure of the ethosomes. Additionally, the Franz diffusion cell analysis for percutaneous absorption using egg membrane indicated a steady-state flux of the drug from the ethosomes. The formulation's cytotoxicity potential was assessed using the epidermoid carcinoma cell line (A431) through the MTT assay. The results show that the ethosome formulations exhibit cytotoxic activity better than PCHE extract. 1
ConclusionIn sum, the result of this study clearly points out that Pyrus communis extract entrapped in ethosomes, prepared by hot method, displayed a cytotoxic potential against skin cancer cell lines. This ethosomal formulation can be harnessed for skin cancer therapy through further mechanistic analysis and animal studies.
-
-
-
Laccaic Acid A: A Natural Anthraquinone with Potent Anticancer Activity against MDA-MB-231 Cells
Authors: Pankaj Dagur, Suddhasattya Dey, Rajdeep Dey, Hardik Bhatt and Manik GhoshAvailable online: 04 April 2025More LessBackground/AimThis study aims to isolate and evaluate the anticancer potential of laccaic acids from lac dye by utilizing polarity-based fractionation and high-performance liquid chromatography (HPLC).
MethodsIn this study, polarity-based fractionation of lac dye was performed to isolate its constituents. A novel HPLC method was developed for the chromatographic separation of lac dye components, utilizing gradient elution with two solvents: 0.1% (v/v) formic acid in LCMS-grade water (A) and 90:10 acetonitrile HPLC-grade (B) at a flow rate of 0.4 mL/min. This method facilitated the isolation of four key constituents: laccaic acid D, laccaic acid B, laccaic acid C, and laccaic acid A.
ResultsThe purity of these compounds was confirmed via LCMS methods. The anticancer activity of the isolated constituents was evaluated against the MDA-MB-231 cell line using the MTT assay. Notably, laccaic acid A demonstrated significant anticancer activity with an IC50 value of less than 100 nM, comparable to that of Adriamycin. Further investigations into the apoptotic activity of laccaic acid A were conducted using flow cytometry, revealing that laccaic acid A is a non-necrotic and apoptotic inducer. Additionally, considering that an effective anticancer agent may also exhibit antioxidant, anti-inflammatory, and anti-angiogenesis properties, the isolated laccaic acids were accessed for these biological activities.
ConclusionThe results were promising, indicating that laccaic acids could offer a multifaceted approach to cancer treatment. This study highlights the potential of laccaic acids as valuable candidates for anticancer therapy and warrants further investigation into their mechanisms of action and therapeutic efficacy.
-
-
-
Triazole scaffold-based DPP-IV Inhibitors for the management of Type-II Diabetes Mellitus: Insight into Molecular Docking and SAR
Available online: 31 October 2024More LessDiabetes mellitus, characterized as a chronic metabolic disorder or a polygenic syndrome; is increasing at a very fast pace among every group of the population worldwide. It arises due to the inability of the body to produce enough insulin (the hormone responsible for controlling blood sugar levels) or inability to utilize the insulin, leading to hyperglycaemic condition, which, if left uncontrolled gives rise to chronic microvascular and macrovascular complications like retinopathy, neuropathy, nephropathy, coronary artery disease, cognitive impairment, etc. Several therapeutic approaches are available for the treatment of diabetes; among which dipeptidyl peptidase (DPP-IV) inhibitors (gliptins) hold a significant place. DPP-IV is a multifunctional enzyme or a serine exopeptidase that plays an imperative role in cleaving bioactive molecules. DPP-IV causes the breakdown of incretin hormone (GLP-1: Glucagon-like peptide 1 and GIP: Glucose-dependent insulinotropic peptide) that is essential for controlling glycaemic levels in the body. Inhibition of DPP-IV enzyme (DPP-IV inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin) prevents this breakdown, thereby controlling blood glucose levels and saving the patients from deleterious effects of prolonged hyperglycaemic conditions. Triazole-based DPP-IV inhibitors are a significant class of drugs used to treat Type 2 diabetes mellitus in a dose-dependent manner. Clinical trials have demonstrated their efficacy as monotherapy or in combination with other antidiabetic agents. This review highlights the molecular docking studies and structure-activity relationship of potential synthetic derivatives that may act as lead molecules for future drug discovery and yield drug molecules with enhanced efficacy, potency and reduced toxicity profile.
-